The results of phase 1/2 clinical trials of another pan-NOS inhibitor L-NMMA (NG-monomethyl-L-arginine), in triple-negative breast cancer (TNBC) have recently been published [58]. The gene discussed is NOS1; the disease is triple-negative breast carcinoma.